Keyphrases
Interleukin-6
100%
Type I Diabetes
100%
Type 1 Diabetes Mellitus (T1DM)
100%
Liraglutide
100%
Polyneuropathy
100%
Confidence Interval
50%
Inflammatory Cytokines
50%
Placebo
33%
Neuronal Function
33%
Diabetic Neuropathy
33%
Inflammatory Pathways
16%
Inflammation
16%
Immune Response
16%
Placebo-controlled Trial
16%
Clinical Practice
16%
A1 Receptor
16%
Latency
16%
Long-term Treatment
16%
Receptor Agonist
16%
Weight Loss
16%
Glucagon-like
16%
Patient-completed
16%
Anti-neuroinflammation
16%
Albumin-to-creatinine Ratio
16%
Neurophysiological Test
16%
Neuropathy
16%
Anti-inflammatory Properties
16%
Inflammatory Immune Response
16%
Autonomic Function
16%
Targeted Treatment
16%
Titration
16%
Cortical Evoked Potentials
16%
Peripheral Level
16%
Central Level
16%
Brain Evoked Potential
16%
Autonomic Status
16%
Medicine and Dentistry
Interleukin 6
100%
Insulin Dependent Diabetes Mellitus
100%
Liraglutide
100%
Polyneuropathy
100%
Cytokine
50%
Placebo
50%
Diabetic Neuropathy
33%
Cardiovascular System
16%
Creatinine
16%
Glucagon-Like Peptide-1 Agonist
16%
Evoked Potential
16%
Anti-Inflammatory Drug
16%
Targeted Therapy
16%
Autonomic Function
16%
Titrimetry
16%
Neuropathy
16%
Evoked Cortical Response
16%
Neuroscience
Interleukin 6
100%
Polyneuropathy
100%
Liraglutide
100%
Proinflammatory Cytokine
50%
Placebo
50%
Diabetic Neuropathy
33%
Creatinine
16%
Peripheral Neuropathy
16%
Anti-Inflammatory
16%
Evoked Potential
16%
Evoked Cortical Response
16%
Glucagon-Like Peptide-1 Agonist
16%
Immunology and Microbiology
Proinflammatory Cytokine
100%
Interleukin 6
100%
Agonist
33%
Evoked Response
33%
Evoked Cortical Response
33%